Rituximab
Treatment for Chronic Kidney Disease Due To Glomerulonephritis
Typical Dosage: 375 mg/m² IV weekly for 4 weeks OR 1000 mg IV twice 2 weeks apart
Effectiveness
78%
Safety Score
35%
Clinical Trials
80
Participants
8K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
35
DangerousModerateSafe
Treatment Details
Dosage Range
375 mg/m² IV weekly for 4 weeks OR 1000 mg IV twice 2 weeks apart
Time to Effect
1-3 months
Treatment Duration
Induction, then maintenance every 6-12 months
Evidence Quality
HIGHNumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
35(Treat 35 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$15,000
Monitoring:$800
Side Effect Mgmt:$500
Total Annual:$16,300
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$120,000/QALY
QALYs Gained
1.7
Outcome-Based Costs
Cost per Responder
$20,897
Cost per Remission
$27,167
Comparison vs Cyclophosphamide (induction)
Cost Difference
+$9,800/year
More expensive
QALY Difference
+0.30 QALYs
Better outcomes
Dominance
No dominance
Rituximab Outcomes
for Chronic Kidney Disease Due To Glomerulonephritis
Efficacy Outcomes
Overall Effectiveness
+78%
Response Rate
+78%
Remission Rate
+60%
Common Side Effects
Infusion reactions
+25%
Infections
+15%
Hypogammaglobulinemia
+7%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov